Payment overview · 2025
General Payments
$86,543.43
149 reported records · 9 companies
Healthcare provider profile · identity verified
Tracy W Norfleet, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1487680377
Verified facts
What the public records show
CMS Open Payments records show Tracy W Norfleet, MD received $86,543.43 in general payments during 2025 across 149 reported records.
Lilly USA, LLC accounted for 95.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82,279.15 | 95.1% | 126 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $3,652.01 | 4.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $351.88 | 0.4% | 8 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $120.29 | 0.1% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $43.08 | 0.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.61 | 0.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.53 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.04 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.84 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,150.00 | 55 |
| Travel and Lodging | $14,906.43 | 36 |
| Consulting Fee | $7,521.00 | 6 |
| Food and Beverage | $1,966.00 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63,514.97 | 97 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $3,652.01 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $299.34 | 5 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $120.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.58 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.54 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.54 | 3 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
57 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 815 | 210 |
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 100 |
| Omeprazole | Omeprazole | 355 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 86 |
| Gabapentin | Gabapentin | 298 | 73 |
| Lisinopril | Lisinopril | 283 | 77 |
| Losartan Potassium | Losartan Potassium | 265 | 67 |
| Metformin Hcl | Metformin Hcl | 263 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 74 |
| Furosemide | Furosemide | 228 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 50 |
| Ezetimibe | Ezetimibe | 164 | 51 |
| Alprazolam | Alprazolam | 161 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 152 | 40 |
| Carvedilol | Carvedilol | 147 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 40 |
| Simvastatin | Simvastatin | 141 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 30 |
| Spironolactone | Spironolactone | 130 | 34 |
| Tramadol Hcl | Tramadol Hcl | 123 | 29 |
| Allopurinol | Allopurinol | 121 | 30 |
| Potassium Chloride | Potassium Chloride | 119 | 36 |
| Famotidine | Famotidine | 114 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 112 | 16 |
| Sertraline Hcl | Sertraline Hcl | 110 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 18 |
| Montelukast Sodium | Montelukast Sodium | 109 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 101 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 22 |
| Glipizide Er | Glipizide | 89 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 16 |
| Trazodone Hcl | Trazodone Hcl | 86 | 25 |
| Meloxicam | Meloxicam | 83 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 25 |
| Metformin Hcl Er | Metformin Hcl | 80 | 25 |
| Bupropion Xl | Bupropion Hcl | 79 | 23 |
| Eliquis | Apixaban | 75 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 71 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 17 |
| Baclofen | Baclofen | 67 | 15 |
| Ozempic | Semaglutide | 66 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 17 |
| Ibuprofen | Ibuprofen | 59 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 57 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 15 |
| Telmisartan | Telmisartan | 54 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 12 |
| Synthroid | Levothyroxine Sodium | 44 | 11 |
| Valacyclovir | Valacyclovir Hcl | 44 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 17 |
| Jardiance | Empagliflozin | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 38 | 11 |
| Hydrocortisone | Hydrocortisone | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 13 |
| Atenolol | Atenolol | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Nystatin | Nystatin | 33 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Indomethacin | Indomethacin | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $86,543.43 · 149 records | Lilly USA, LLC | AIRSUPRA, APRETUDE, AREXVY, CONTRAVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, MOUNJARO, Ozempic, QSYMIA, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error